Bioluminescence Imaging of Human Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Myocardial Infarction
Bioluminescence Imaging of Human Embryonic Stem Cell-Derived Endothelial Cells for Treatment of Myocardial Infarction
复制标题
人胚胎干细胞衍生的内皮细胞的生物发光成像用于治疗心肌梗塞。
DOI：
10.1007/7651_2013_15
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Li, Zongjin
中科院分区：
文献类型：
--
作者：
Su, Weijun;Leng, Liang;Li, Zongjin
心肌梗塞是全世界死亡和发病的主要原因，目前的治疗无法解决潜在的疤痕和细胞损失，这是梗塞后心力衰竭的主要原因。内皮祖细胞移植治疗性血管生成和/或血管生成这一新策略有望增加缺血区域的血流量，从而重建受损的心脏并逆转心力衰竭。鉴于自我更新和分化为几乎所有细胞类型的潜力，人胚胎干细胞（hESC）可以通过产生大量内皮细胞来治疗缺血性心脏病的血管生成和/或血管发生，从而提供治疗细胞的替代来源。此外，为了充分了解植入的 hESC 或 hESC 衍生物的命运，研究人员需要监测活体动物体内细胞随时间的运动情况。在本章中，我们描述了应用生物发光报告基因成像来追踪移植的 hESC 衍生内皮细胞以治疗心肌梗塞。还将讨论从 hESC 诱导内皮细胞的技术。
Myocardial infarction is a leading cause of mortality and morbidity worldwide, and current treatments fail to address the underlying scarring and cell loss, which is a major cause of heart failure after infarction. The novel strategy, therapeutic angiogenesis and/or vasculogenesis with endothelial progenitor cells transplantation holds great promise to increase blood flow in ischemic areas, thus rebuild the injured heart and reverse the heart failure. Given the potential of self-renewal and differentiation into virtually all cell types, human embryonic stem cells (hESCs) may provide an alternate source of therapeutic cells by allowing the derivation of large numbers of endothelial cells for therapeutic angiogenesis and/or vasculogenesis of ischemic heart diseases. Moreover, to fully understand the fate of implanted hESCs or hESC derivatives, investigators need to monitor the motility of cells in living animals over time. In this chapter, we describe the application of bioluminescence reporter gene imaging to track the transplanted hESC-derived endothelial cells for treatment of myocardial infarction. The technology of inducing endothelial cells from hESCs will also be discussed.